Status:
UNKNOWN
Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborating Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
Acromegaly
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
Previous studies addressing preoperative somatostatin analogs (SSA) treatment and subsequent surgical cure rates are conflicting, reporting a benefit, or no difference between groups. And most reporte...
Detailed Description
Acromegaly is a rare disease, caused by a growth hormone (GH)-secreting adenoma and in even more seldom instances (about 1%) due to excessive growth hormone-releasing hormone (GHRH) secretion, usually...
Eligibility Criteria
Inclusion
- patients with newly diagnosed acromegaly due to GH-secreting macro-adenomas.
- newly diagnosed, previously untreated patients with GH nadir more than 2.5 μg/L during a standard 75-g, 2-h oral glucose tolerance test (OGTT)
- pituitary macroadenomas (maximum diameter \>1 cm) verified by a pituitary magnetic resonance imaging (MRI) scan
- age between 18 and 80 yr.
Exclusion
- immediate surgery indicated by clinical criteria
- pregnancy
- contraindications to MRI scan
- patients judged not suitable to participate in the study for other reasons such as personality disorders and alcohol abuse.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2010
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00993356
Start Date
January 1 2004
End Date
December 1 2010
Last Update
October 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510080